Assess Safety and PK of ADASUVE® in Children and Adolescents Using an Antipsychotic Medication
- Study Title
- Study to Assess the Safety and Pharmacokinetics of ADASUVEֲ® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication
- Teva Identifier
- TV571-CNS-10018
- ClinicalTrials.gov Identifier
- NCT02184767
- Study Status
- Completed
- Trial Condition(s)
- BiPolar
- Interventions
- Drug: ADASUVEֲ®
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Child
- Age Range
- 10 Years to 17 Years
- Trial Duration
- 07/01/2014 - 05/01/2015
- Phase
- Phase 1
